Indication
Rheumatoid Arthritis
The Rheumatoid Arthritis pipeline: 61 tracked drugs, 22 approved for this indication.
22 approved / phase 49 Phase 313 Phase 215 Phase 12 preclinical / unstaged
Compare the share prices of listed companies in Rheumatoid Arthritis →
Total attributable cost
$32.7B
$24,068/patient
Drug spend
$13.4B
$9,885/patient
41% of total cost is drugs
All severities and treatment regimens (US estimate) · US